Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Solymbic

EU flag

EMA defends Humira redaction policy from transparency criticism

Regulator says spirit of trial transparency intact after its handling of AbbVie reports

- PMLiVE

Amgen banking on three launches in 2015

New products on the way for cholesterol, heart failure and melanoma

- PMLiVE

Abraxane on course for lung cancer indication in EU

CHMP backs news indication for Celgene drug

EU flag

Antibiotics among 7 new drugs backed by EMA

The Medicines Company’s Orbactiv and Cubist’s Sivextro set for European approval

- PMLiVE

CHMP thumbs up for Novo’s obesity drug Saxenda

Diabetes drug liraglutide on course for new indication in EU

- PMLiVE

FDA approves AbbVie’s Duopa in advanced Parkinson’s

Drug is administered into the stomach via a tube

- PMLiVE

EC clears AbbVie’s oral hepatitis C regimen

Viekirax and Exviera offer competition to Gilead’s Sovaldi

- PMLiVE

Amgen and Kite in $1bn cancer immunotherapy tie up

Latest major research deal in growing area of oncology

Novartis day

FDA close to first biosimilar approval

US regulator’s advisory board recommends Novartis’ version of Amgen’s Neupogen

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

- PMLiVE

AbbVie wins key approval for hep C pill Viekira Pak

Prices all-oral treatment fractionally lower than rivals from Gilead

- PMLiVE

Orexigen’s obesity pill Mysimba set for European approval

But sales of the treatment are only predicted to reach $200m by 2016

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links